[1]叶廷巧,赵 亮,庾 辉,等.托伐普坦治疗心力衰竭合并肾功能不全的研究[J].医学信息,2020,33(15):69-72.[doi:10.3969/j.issn.1006-1959.2020.15.022]
　YE Ting-qiao,ZHAO Liang,YU Hui,et al.Tolvaptan in the Treatment of Heart Failure with Renal Insufficiency[J].Medical Information,2020,33(15):69-72.[doi:10.3969/j.issn.1006-1959.2020.15.022]
点击复制

托伐普坦治疗心力衰竭合并肾功能不全的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年15期
页码:
69-72
栏目:
论著
出版日期:
2020-08-01

文章信息/Info

Title:
Tolvaptan in the Treatment of Heart Failure with Renal Insufficiency
文章编号:
1006-1959（2020）15-0069-04
作者:
叶廷巧1; 赵 亮1; 庾 辉1; 龚 倩1; 郑 曦2
1.绵阳市中心医院心血管内科，四川 绵阳 621000；2.重庆市南川区人民医院心血管内科，重庆 408400
Author(s):
YE Ting-qiao1; ZHAO Liang1; YU Hui1; GONG Qian1; ZHENG Xi2
1.Department of Cardiovascular Medicine,Mianyang Central Hospital,Mianyang 621000,Sichuan,China;2.Department of Cardiovascular Medicine,Nanchuan District People’s Hospital,Chongqing 408400,China
关键词:
托伐普坦; 心力衰竭; 肾功能不全; 利尿剂
Keywords:
Tolvaptan; Heart failure; Renal insufficiency; Diuretics
分类号:
R541.6；R692
DOI:
10.3969/j.issn.1006-1959.2020.15.022
文献标志码:
A
摘要:
目的 观察托伐普坦治疗心力衰竭合并肾功能不全的临床疗效及安全性。方法 选取绵阳市中心医院心血管内科2017年1月~2019年1月收治的心力衰竭合并肾功能不全的110例患者，随机分为对照组和托伐普坦组，各55例。对照组给予常规对症治疗，托伐普坦组在对照组基础之上加用托伐普坦，比较两组治疗后1周和1个月的临床疗效及不良反应发生情况。结果 托伐普坦组治疗后1周和1个月的总有效率、24 h尿量、血清钠、6 min步行距离均高于对照组，差异有统计学意义（P＜0.05）；托伐普坦组治疗后1周和1个月的proBNP水平、体重均低于对照组，差异有统计学意义（P＜0.05）；托伐普坦组治疗后1月的血肌酐、不良反应、再住院率和心衰纠正时间均低于对照组，差异有统计学意义（P＜0.05）。结论 托伐普坦能明显改善心力衰竭合并肾功能不全患者的临床症状、缩短心衰纠正时间、延缓肾功能恶化，同时不良反应发生率低。
Abstract:
Objective To observe the clinical efficacy and safety of tolvaptan in the treatment of heart failure with renal insufficiency.Methods A total of 110 patients with heart failure and renal insufficiency who were admitted to the Department of Cardiovascular Medicine of Mianyang Central Hospital from January 2017 to January 2019 were selected and randomly divided into control group and tolvaptan group, with 55 cases in each group. The control group was given conventional symptomatic treatment, and the tolvaptan group was given tolvaptan on the basis of the control group. The clinical efficacy and adverse reactions of the two groups were compared one week and one month after treatment.Results The total effective rate, 24-hour urine output, serum sodium, and 6-min walking distance in the tolvaptan group at 1 week and 1 month after treatment were higher than those in the control group,the difference was statistically significant (P＜0.05); tolvaptan the proBNP level and body weight of the tan group were lower than those of the control group one week and one month after treatment,the difference was statistically significant (P＜0.05); the blood creatinine, adverse reactions, and rehospitalization rate of the tolvaptan group one month after treatment time to correct heart failure was lower than that of the control group,the difference was statistically significant (P＜0.05).Conclusion Tolvaptan can significantly improve the clinical symptoms of patients with heart failure and renal insufficiency, shorten the correction time of heart failure, delay the deterioration of renal function, and reduce the incidence of adverse reactions.

参考文献/References:

[1]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.[2]Damman K,Valente MAE,Voors AA,et al.Renal impairment,worsening renal function,and outcome in patients with heart failure:an updated meta-analysis[J].European Heart Journal,2014,35(7):455-469.[3]Faris R,Flather MD,Purcell H,et al.Diuretics for heart failure[J].Cochrane Database Syst Rev,2016,2(2):CD003838.[4]Imamura T,Kinugawa K.Prognostic Impacts of Hyponatremia,Renal Dysfunction,and High-Dose Diuretics During a 10-Year Study Period in 4,087 Japanese Heart Failure Patients[J].International Heart Journal,2016,57(5):657-658.[5]姜晨煜,何也,傅强.心肾综合征的治疗现状及展望[J].广东医学,2018,39(10):1578-1582.[6]Hori M.Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure[J].Future Cardiology,2013,9(2):163-176.[7]王立立,韩爽,张至,等.不同剂量托伐普坦治疗老年慢性心力衰竭伴利尿剂抵抗患者的疗效与安全性观察[J].中华老年心脑血管病杂志,2019,21(4):375-378.[8]Kinugawa K,Sato N,Inomata T,et al.Efficacy and Safety of Tolvaptan in Heart Failure Patients With Volume Overload-An Interim Result of Post-Marketing Surveillance in Japan[J].Circulation Journal Official Journal of the Japanese Circulation Society,2014,78(4):844-852.[9]Tamaki S,Sato Y,Yamada T,et al.Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction-Prospective Randomized Controlled Study[J].Circulation Journal Official Journal of the Japanese Circulation Society,2017,81(5):740.[10]Shirakabe A,Hata N,Yamamoto M,et al.Immediate Administration of Tolvaptan Prevents the Exacerbation of Acute Kidney Injury and Improves the Mid-Term Prognosis of Patients With Severely Decompensated Acute Heart Failure[J].Circulation Journal,2014,78(4):911-921.[11]Alskaf E,Tridente A,Al-Mohammad A.Tolvaptan for Heart Failure,Systematic Review and Meta-analysis of Trials[J].Heart,2016,102(Suppl 6):A1. [12]Uemura Y,Shibata R,Takemoto K,et al.Safety and Efficacy of Long-Term Use of Tolvaptan in Patients With Heart Failure and Chronic Kidney Disease[J].Circulation Journal,2017,81(11):1736.[13]Udelson JE,Mcgrew FA,Flores E,et al.Multicenter,Randomized,Double-Blind,Placebo-Controlled Study on the Effect of Oral Tolvaptan on Left Ventricular Dilation and Function in Patients With Heart Failure and Systolic Dysfunction[J].Journal of the American College of Cardiology,2007,49(22):2151-2159.

相似文献/References:

[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
　GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,31(15):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]程 林.重组人脑利钠肽用于重症急性心肌炎伴 心力衰竭患者治疗的临床研究[J].医学信息,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
　CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,31(15):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[3]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
　HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,31(15):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[4]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
　LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(15):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[5]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,31(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
　HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,31(15):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[6]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
　ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Medical Information,2018,31(15):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[7]施国富,吴春阳,施亚明,等.血浆脑钠肽对射血分数保留心力衰竭患者的诊断价值研究[J].医学信息,2018,31(16):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
　SHI Guo-fu,WU Chun-yang,SHI Ya-ming,et al.Diagnostic Value of Plasma Brain Natriuretic Peptide in Patients with Heart Failure Preserved by Ejection Fraction[J].Medical Information,2018,31(15):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
[8]李 宁,胡硕强.心脏再同步治疗心力衰竭的文献计量分析[J].医学信息,2018,31(19):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
　LI Ning,HU Shou-qiang.Bibliometric Analysis of Cardiac Resynchronization in the Treatment of Heart Failure[J].Medical Information,2018,31(15):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
[9]颜 琼,王 静,胡 聪.慢性心力衰竭患者半年内重返住院的调查分析与对策[J].医学信息,2018,31(20):173.[doi:10.3969/j.issn.1006-1959.2018.20.055]
　YAN Qiong,WANG Jing,HU Cong.Investigation and Countermeasures of Patients with Chronic Heart Failure Returning to Hospital within Half a Year[J].Medical Information,2018,31(15):173.[doi:10.3969/j.issn.1006-1959.2018.20.055]
[10]杨锦龙,刘 欢.甲状腺激素测定在高血压心力衰竭患者中的临床意义[J].医学信息,2018,31(22):96.[doi:10.3969/j.issn.1006-1959.2018.22.026]
　YANG Jin-long,LIU Huanc.Clinical Signifcance of Changes of Serum Thyroid Hormone Levels in Hypertensive Patients with Chronic Heart Failure[J].Medical Information,2018,31(15):96.[doi:10.3969/j.issn.1006-1959.2018.22.026]
[11]纪东华.托伐普坦治疗AMI合并心力衰竭的疗效及对患者血清hs-CRP、NT-proBNP表达的影响[J].医学信息,2019,32(16):127.[doi:10.3969/j.issn.1006-1959.2019.16.041]
　JI Dong-hua.Efficacy of Tolvaptan in the Treatment of AMI Complicated with Heart Failure and its Effect on Serum hs-CRP and NT-proBNP Expression[J].Medical Information,2019,32(15):127.[doi:10.3969/j.issn.1006-1959.2019.16.041]

更新日期/Last Update: 1900-01-01